SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as discussions swirl around potential partnerships with rivals like AMD and Apple for its foundry business, fueled by reports and government initiatives to bolster domestic chip manufacturing. Community members debate the implications of these partnerships, potential for revenue growth, and impact on Intel's valuation, with some expressing optimism about a turnaround driven by government support and AI advancements. Others caution about execution risks and the need for concrete results to justify the stock's recent gains.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is generating buzz as the community rallies to get it trending, emphasizing its active development team and engaged community. Discussions highlight the coin's utilities, ongoing contests, and upcoming staking features, positioning it as more than just another meme coin in the Solana ecosystem. Some users have also expressed excitement for 'Uptober'.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending due to positive sentiment around its potential in the weight loss and diabetes drug market, fueled by a new facility announcement and promising trial data for its oral GLP-1.  The community is actively discussing its competitive positioning against Novo Nordisk and speculating on potential acquisitions in the sector. Some investors are also considering the impact of potential government actions, such as tariffs and direct consumer pricing initiatives.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is trending as chatter revolves around a potential collaboration with Intel as a foundry customer, sparking debate about its impact and the competitive landscape with TSMC and Samsung. Community members are actively discussing the news' validity, potential benefits, and AMD's overall valuation amidst the ever-evolving semiconductor sector. Technical analysis and price target speculation are also contributing to the heightened interest in the stock.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is experiencing volatility, with community discussions focusing on a potential link to ChatGPT's reduced reliance on Reddit data, impacting its AI narrative and prompting a sharp sell-off. Dip buyers are active, while others point to strong institutional ownership and upcoming earnings as reasons for optimism, despite concerns around political bias on the platform. Some traders are also drawing parallels between RDDT and RUM, noting potential political catalysts and high short interest in RUM.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DKNG is trending downwards amidst concerns that prediction markets, like Kalshi and Robinhood, are gaining traction and posing a competitive threat. The community is actively discussing the potential impact on DraftKings' market share and revenue, with some criticizing the company's leadership for not adapting quickly enough. Investors are also monitoring broader industry trends, including regulatory developments and the potential for increased competition.

Rezolve AI Plc operates in the mobile commerce industry with its cutting-edge engagement platform powered by artificial intelligence and machine learning. It develops AI-based mobile commerce and engagement solutions, simplifying the purchasing process by providing relevant information and facilitating seamless transactions with a single tap. The company enables retailers, brands, and manufacturers to create dynamic connections with consumers across mobile and desktop devices. Rezolve Ai was founded in 2016 and is headquartered in London, the United Kingdom.

Rezolve AI PLC .

Rezolve AI Limited

Rezolve AI ($RZLV) is trending due to significant volatility following earnings, with community debate centered on the company's future growth and valuation. A short report from Fuzzy Panda is adding to the uncertainty, while bulls point to raised ARR guidance and potential short squeeze setups. The stock's price action and high trading volume are attracting attention as investors digest conflicting viewpoints.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid social media discussions spurred by Elon Musk's call to cancel subscriptions, citing concerns over content aimed at children and related controversies. The community is debating the impact of these sentiments on the stock's value, while some defend Netflix, pointing to its strong fundamentals and subscriber base. Technical analysis suggests key support and resistance levels are being closely watched as the stock navigates market sentiment.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors digest recent earnings and future guidance, with community members weighing the potential for short-term gains amidst broader discussions of memory market cycles. Despite strong financial results and tailwinds from increased data center spending and AI, some traders are expressing caution, citing overbought conditions and potential pullbacks. Community talking points include discussions around potential squeeze plays, price targets, and the impact of broader market trends.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending as discussions revolve around potential catalysts including a deal with TrumpRx and investment in US manufacturing, which could boost the stock. The community is weighing the impact of these developments on Pfizer's valuation, noting institutional buying and potential for future growth in areas like weight-loss drugs. Some investors believe that the stock is undervalued and anticipate a significant rise.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Equity

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 


Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Best Momentum Stock to Buy for August 15th

ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Options Traders Betting on a Big Move in Harrow Stock?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Harrow Health, Inc reported a wider first-quarter loss on Thursday but reaffirmed its full-year revenue outlook, prompting a pickup in retail trading activity.The eyecare pharmaceutical firm posted a net loss of $17.8 million, or 38 cents per share, compared with a loss of $13.6 million, or 28 cents per share, a year earlier.&nbsp;Harrow shares closed at $23.59, down 4.07% on Thursday, and dropped further in after-hours trading, falling $2.49, or 10.56% to $21.10.Revenue rose 38% year-over-year to $47.8 million, driven by increased uptake of Vevye, a prescription ophthalmic drug for dry eye disease.&nbsp;Vevye recorded $21.5 million in sales during the quarter.The company cited strong early demand from its new ‘Vevye Access for All’ program, launched in mid-March, with prescription volumes at specialty pharmacy PhilRx more than quadrupling.“Our Vevye refill rate continues to be buoyant, with the average covered patient receiving nine refills,” CEO Mark L. Baum said in a statement.Harrow reaffirmed its 2025 revenue target of over $280 million, slightly below analysts’ average estimate of $283.2 million.&nbsp;The company said it expects continued commercial momentum from its Iheezo and Triesence products, along with contributions from pending pipeline accounts.Management also reiterated its focus on strategic acquisitions to augment its U.S. commercial platform, calling out opportunities to add “high-quality ophthalmic pharmaceutical assets.”Sentiment on Stocktwits was described as "extremely bullish," amid a 2,200% surge in 24-hour message volume.One user expressed strong enthusiasm for the stock, commenting that there was "never a bad price to buy HROW" and that no matter the outcome, it's always "good news."&nbsp;<stembedurl>https://stocktwits.com/dpen1000/message/614022779</stembedurl>Another user highlighted the potential for VEVYE’s continued growth, noting that if it maintains its 35% quarter-over-quarter increase, the product alone could contribute $150 million in revenue for 2025.<stembedurl>https://stocktwits.com/HROW200/message/614007884</stembedurl>The stock has declined over 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue

The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue target of over $280 million.

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Stock Index Futures Gain With All Eyes on Fed Rate Decision

March S&P 500 E-Mini futures (ESH25) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the Federal Reserve’s policy decision and Chair Jerome Powell’s comments.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

0 to 25,000

25,000 to 50,000

50,000 to 75,000

75,000 to 100,000

How many jobs did the U.S. add in September? Vote below + drop your exact prediction in the comments. 
 
*Powered by Polymarket

HROW
Harrow Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HROW News

HROW Harrow Health Inc